Hizal Mutlu, Sendur Mehmet Ali, Bilgin Burak, Bulent Akinci Muhammed, Sener Dede Didem, Yalcin Bulent
Ankara Yildirim Beyazit University, Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
J BUON. 2019 Jul-Aug;24(4):1367-1370.
Chemoradiotherapy (CRT) and chemotherapy in the perioperative or postoperative settings are the different neoadjuvant/adjuvant treatment approaches for resectable gastric cancer. After the results of the ARTIST trial, CRT lost its importance on a large scale in the adjuvant setting. Also, according to the results of the CRITICS trial, CRT does not seem beneficial in the perioperative treatment setting. The beneficial effect of neoadjuvant/adjuvant radiotherapy as a therapeutic option became more questionable as the evidence grows, but still needs further studies to identify its effects on a subgroup of patients who have R1 or <D2 dissection and/or lymph node involvement.
化疗放疗（CRT）以及围手术期或术后化疗是可切除胃癌不同的新辅助/辅助治疗方法。在ARTIST试验结果公布后，CRT在辅助治疗方面在很大程度上失去了其重要性。此外，根据CRITICS试验结果，CRT在围手术期治疗中似乎并无益处。随着证据的增加，新辅助/辅助放疗作为一种治疗选择的有益效果变得更具争议性，但仍需要进一步研究以确定其对有R1切除或<D2清扫和/或淋巴结受累的患者亚组的影响。
